Loading

Hunter BioDiscovery

June 16, 2025
Company Presentation
Tools/Drug Development Support Tech
Founded by serial entrepreneurs and Harvard professors John Iafrate and David Weitz, Hunter BioDiscovery designed an AI-guided, high-throughput platform called FlowMatrixTM to rapidly assess drug synergy and synthetic lethality in live cells to identify novel drug combinations, discover new biologic insights, overcome drug resistance, improve therapeutic index and drug response to treat cancer.
Hunter BioDiscovery
Company HQ City: Millbury
Company HQ State: MA
Company HQ Country: United States
Year Founded: 2015
Lead Product in Development: ATR combination with anti-infective for oncology indication

CEO

Arlinda Lee, PhD

Year Founded

2015

Development Phase of Lead Product

Discovery

Number of Unlicensed Products Looking for Licensing

3+

When you expect your next catalyst update?

Results of combination in mice

What is your next catalyst (value inflection) update?

July 2025

Website

https://www.hunter.bio/home
Primary Speaker
Arlinda Lee
Arlinda Lee, PhD
CEO
Hunter Biodiscovery

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS